Goldman Sachs’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,859,760
| Closed | -$35.1M | – | 5563 |
|
|
2019
Q3 | $35.1M | Sell |
1,859,760
-1,989,634
| -52% | -$22.8M | 0.01% | 1354 |
|
|
2019
Q2 | $45.3M | Buy |
3,849,394
+560,119
| +17% | +$6.78M | 0.01% | 1203 |
|
|
2019
Q1 | $44.9M | Buy |
3,289,275
+527,103
| +19% | +$6.83M | 0.01% | 1221 |
|
|
2018
Q4 | $28.3M | Buy |
2,762,172
+1,572,396
| +132% | +$20.1M | 0.01% | 1525 |
|
|
2018
Q3 | $19.8M | Sell |
1,189,776
-117,744
| -9% | -$2.13M | 0.01% | 1933 |
|
|
2018
Q2 | $20.7M | Sell |
1,307,520
-387,567
| -23% | -$5.89M | 0.01% | 1852 |
|
|
2018
Q1 | $21.5M | Buy |
1,695,087
+33,090
| +2% | +$479K | 0.01% | 1801 |
|
|
2017
Q4 | $19M | Buy |
1,661,997
+145,503
| +10% | +$1.62M | ﹤0.01% | 1978 |
|
|
2017
Q3 | $18.6M | Buy |
1,516,494
+798,105
| +111% | +$8.32M | ﹤0.01% | 2049 |
|
|
2017
Q2 | $8.23M | Buy |
718,389
+49,304
| +7% | +$912K | ﹤0.01% | 2657 |
|
|
2017
Q1 | $13.9M | Buy |
669,085
+40,905
| +7% | +$906K | ﹤0.01% | 2159 |
|
|
2016
Q4 | $13.1M | Sell |
628,180
-77,027
| -11% | -$2M | ﹤0.01% | 2255 |
|
|
2016
Q3 | $23.1M | Sell |
705,207
-283,550
| -29% | -$8.64M | 0.01% | 1779 |
|
|
2016
Q2 | $24.7M | Buy |
988,757
+620,953
| +169% | +$16.8M | 0.01% | 1639 |
|
|
2016
Q1 | $9.01M | Sell |
367,804
-194,298
| -35% | -$4.5M | ﹤0.01% | 2301 |
|
|
2015
Q4 | $18.6M | Buy |
562,102
+181,076
| +48% | +$6.12M | 0.01% | 1804 |
|
|
2015
Q3 | $12.5M | Buy |
381,026
+63,653
| +20% | +$2.71M | ﹤0.01% | 2076 |
|
|
2015
Q2 | $16.8M | Sell |
317,373
-57,322
| -15% | -$2.08M | 0.01% | 1921 |
|
|
2015
Q1 | $10.8M | Buy |
374,695
+162,346
| +76% | +$4.45M | ﹤0.01% | 2236 |
|
|
2014
Q4 | $6.18M | Buy |
+212,349
| New | +$3.81M | ﹤0.01% | 2793 |
|
Goldman Sachs's ALDR Position: Q4 2019 in Review
Goldman Sachs sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,859,760 shares — an estimated $35.1M sold.
Goldman Sachs first reported a position in ALDR in Q4 2014 and held it in 20 quarters. The position peaked at $45.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Goldman Sachs reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Goldman Sachs sold 1,859,760 Alder Biopharmaceuticals shares in Q4 2019, an estimated $35.1M.
- Goldman Sachs first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 20 quarters.
- Goldman Sachs's Alder Biopharmaceuticals position peaked at $45.3M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.